[Human monoclonal antibody to B-lymphocyte stimulator (belimumab) and humanized anti-LFA-1 monoclonal antibodies (efalizumab)].
Sawada
Tetsuji
T
Department of Allergy and Rheumatology, University of Tokyo School of Medicine.
Hashimoto
Shiori
S
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D053264:B-Cell Activating Factor / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D016169:Lymphocyte Function-Associated Antigen-1 / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053264:B-Cell Activating Factor; D016169:Lymphocyte Function-Associated Antigen-1; C511911:belimumab; C472181:efalizumab